Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Revolution Medicines $500 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
AC Immune $80 million at-the-market offering
We advised AC Immune on the offering
GSK collaboration with Flagship Pioneering
We are advising GSK on the transaction
Clariane €92 million reserved capital increase and €237 million rights offering
We advised Clariane on its refinancing transactions
IDEAYA Biosciences $302.5 million equity offering
The common stock is listed on the Nasdaq Global Select Market
Recursion Pharmaceuticals $230 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
InflaRx $75 million at-the-market offering
The shares are listed on the Nasdaq Global Market
Tempus AI $410 million IPO
The stock is listed on the Nasdaq Global Select Market
ProKidney $140 million follow-on offerings
We advised ProKidney on the offering
Royalty Pharma $1.5 billion senior notes offering
We advised Royalty Pharma on its investment-grade notes offering